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The 2016/17 mid-season vaccine effectiveness esti-
mate against influenza A(H3N2) was 15% (95% con-
fidence interval: −11 to 35) in Navarre. Comparing to 
individuals unvaccinated in the current and four prior 
seasons, effectiveness was 24% for current and 3–4 
prior doses, 61% for current and 1–2 prior doses, 42% 
for only current vaccination, and 58% for 3–4 prior 
doses. This suggests moderate effectiveness for dif-
ferent combinations of vaccination in the current and 
prior seasons.
During the early 2016/17 influenza season, influenza 
A(H3N2) was the main circulating virus in Europe [1]. 
Although most of the A(H3N2) viruses characterised 
genetically matched the vaccine component, a high 
incidence of severe cases was detected [1,2]. We pre-
sent the 2016/17 mid-season vaccine effectiveness 
(VE) estimates in preventing laboratory-confirmed 
influenza A(H3N2), relative to different combinations of 
current and prior seasonal influenza vaccinations.
Setting and information sources
In the 2016/17 season the A(H3N2) component rec-
ommended for the influenza vaccine in the north-
ern hemisphere was A/HongKong/4801/2014-like 
virus (group 3C.2a) [3], in the 2015/16 season A/
Switzerland/9715293/2013-like (group 3C.3a) [4], and 
in seasons 2012/13 to 2014/15 it was A/Texas/50/2012-
like or A/Victoria/361/2011-like (group 3C.1) [5]. 
The Influenza Surveillance System in Spain reported 
that as of 9 February 2017, 99% of the sentinel detec-
tions of influenza virus were A(H3N2), and sequence 
analysis of the HA1 fragment of the haemagglutinin 
gene found 74% of strains as A/Bolzano/7/2016 (group 
3C.2a1) and 21% as A/HongKong/4801/2014, both of 
which matched the vaccine component [2].
A test-negative case–control study was conducted, 
based on epidemiological and virological surveillance 
of influenza in primary healthcare and hospitals in 
Navarre, northern Spain. The influenza vaccination 
campaign took place in October and November 2016. 
The trivalent inactivated non-adjuvanted vaccine was 
offered free of charge to a target group for vaccination, 
including people aged 60 years or over and those with 
major chronic conditions (body mass index ≥40 kg/m2, 
cancer, liver cirrhosis, dementia, diabetes mellitus, 
immunodeficiency, heart disease, renal disease, res-
piratory disease, rheumatic disease, and stroke).
Influenza vaccine status in seasons 2012/13 to 2016/17 
was obtained from the online regional vaccination reg-
ister [6]. These five seasons were considered because 
for all of them the A(H3N2) component included in the 
vaccine belonged to clade 3C [3-5]. 
Patients were considered to be protected from influ-
enza 14 days after vaccine administration in the cur-
rent season.
Influenza surveillance was based on automatic report-
ing of cases of influenza-like illness (ILI) from all 
primary healthcare physicians and hospitals [7]. A 
sentinel network of primary healthcare physicians was 
requested to take nasopharyngeal and pharyngeal 
swabs from their patients diagnosed with ILI, whose 
symptoms had begun less than five days previously. 
In hospitals, the protocol specified early detection and 
swabbing of all hospitalised patients with ILI. Samples 
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were processed by reverse transcription-polymerase 
chain reaction assay.
Statistical analysis
The study population included persons covered by 
the Navarre Health Service since 2012 (96% of the 
population). All patients who were swabbed between 
1 December 2016 (beginning of continued detection 
of influenza virus) and 31 January 2017 were initially 
considered. Healthcare workers, persons living in nurs-
ing homes, children less than 9 years-old and patients 
hospitalised before ILI symptom onset were excluded. 
We compared seasonal vaccination status in patients 
for whom A(H3N2) influenza virus was detected (cases) 
and in those who were negative for influenza (con-
trols). Crude and adjusted odds ratios (OR) with their 
95% confidence intervals (CI) were calculated using 
logistic regression models. Adjusted models included 
sex, age group (9–24, 25–44, 45–64, 65–84 and ≥ 85 
years), major chronic conditions, month of swabbing, 
and healthcare setting (primary healthcare and hos-
pital). Six categories combining current vaccination 
status with vaccination in the four prior seasons and 
thus distinguishing between frequent and infrequent 
vaccinees were considered [8,9]: current-season vac-
cination and > 2 prior doses, current-season vaccination 
and 1–2 prior doses, current-season vaccination and 
no prior doses, no current-season vaccination and > 2 
prior doses, no current-season vaccination and 1–2 
prior doses, and no current-season vaccination and no 
prior doses (reference group). To compare VE among 
categories, the model was repeated using the category 
with current season vaccination and > 2 prior doses as 
the reference. VE was estimated as a percentage: (1–
OR) × 100.
Early estimation of influenza vaccine 
effectiveness
Of 1,243 ILI initial patients, one case of non-subtyped 
influenza A and two influenza B cases were not further 
Figure 
Effectiveness of current season influenza vaccination and of vaccination in the four prior seasons in preventing laboratory 
confirmed influenza A(H3N2) cases among people ≥ 9 years-old in Navarre, Spain, 1 December 2016–31 January 2017 
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considered. The remaining 1,240 ILI patients were 
included in the study and consisted of 783 (63%) hos-
pitalised patients and 457 primary healthcare patients. 
A total of 591 (48%) were confirmed cases for influenza 
A(H3N2) and were compared with 649 controls nega-
tive for any influenza virus. 
Compared with test-negative controls, A(H3N2) influ-
enza cases had a lower proportion of persons over 65 
years-old (53% (315/591) in cases vs 62% (401/649) 
in controls; p = 0.003), with major chronic conditions 
(59% vs 71%; p < 0.001; Table 1) and who were treated 
in hospital (51% (300/591) vs 74% (483/649; p < 0.001)). 
Among the cases, 41% had received the 2016/17 sea-
sonal vaccine, vs 50% of the controls (p = 0.001) (Table 
1).
The overall adjusted estimate of influenza VE was 15% 
(95%CI: –11 to 35). The estimates were similar in the 
analysis of the target group for vaccination (16%), and 
were somewhat better in persons younger than 65 
years (24%) than in the older age group (≥ 65 years; 
11%). The point estimates suggested higher VE in out-
patients (48%; 95%CI: –1 to 65) than in inpatients (0%; 
95%CI: –38 to 27) (Table 2).
In the pooled analysis of all patients, as compared with 
individuals unvaccinated in the current and four prior 
seasons, the preventive effect was 61% (95%CI: 30 to 
78) in those vaccinated in the current season who had 
also received 1–2 doses of vaccine in the prior sea-
sons, 24% (95%  CI: –6 to 46) in those vaccinated in 
the current season after 3–4 doses, 42% (95%  CI: –5 
to 68) in those vaccinated only in the current season, 
58% (95%CI: 26 to 78) in individuals without current 
vaccination but with > 2 prior doses, and 44% (95% CI: 
3 to 68) in those unvaccinated in the current season 
but with 1–2 prior doses. Current and 1–2 dose prior 
season vaccination, or current season non-vaccination 
in people with > 2 prior doses showed statistically sig-
nificant higher protection than current and > 2 prior sea-
son vaccinations (Figure). 
Table 1
Characteristics, according to the healthcare setting and test result, of patients with medically-attended influenza-like illness 
included in the test-negative case–control analysis, Navarre, Spain, 1 December 2016–31 January 2017 (n = 1,240 patients)
Characteristics
All patients Hospitalised patients Primary healthcare patients
Controls Cases Controls Cases Controls Cases
N % N % N % N % N % N %
Age groups in years 
9–24 37 6 56 9 14 3 1 0 23 14 55 19
25–44 76 12 99 17 22 5 7 2 54 33 92 32
45–64 135 21 121 20 80 17 33 11 55 33 88 30
65–84 269 41 197 33 236 49 143 48 33 20 54 19
≥ 85 132 20 118 20 131 27 116 39 1 1 2 1
Sex 
Male 331 51 274 46 269 56 151 50 62 37 123 42
Female 318 49 317 54 214 44 149 50 104 63 168 58
Residence 
Rural 237 37 213 36 213 44 154 51 24 15 59 20
Urban 412 63 378 64 270 56 146 49 142 86 232 80
Major chronic conditions 
No 189 29 242 41 78 16 43 14 111 67 199 68
Yes 460 71 349 59 405 84 257 86 55 33 92 32
Month of swabbing 
December 159 24 139 24 106 22 58 19 53 32 81 28
January 490 76 452 76 377 78 242 81 113 68 210 72
Target group for vaccinationa 
No 124 19 182 31 36 7 11 4 88 53 171 59
Yes 525 81 409 69 447 93 289 96 78 47 120 41
2016/17 season vaccine 
No 327 50 351 59 205 42 113 38 122 73 238 82
Yes 322 50 240 41 278 58 187 62 44 27 53 18
Total 649 100 591 100 483 100 300 100 166 100 291 100 
a Target group for vaccination includes people ≥ 60 years old and people with major chronic conditions (body mass index ≥40 kg/m2, cancer, 
liver cirrhosis, dementia, diabetes mellitus, immunodeficiency, heart disease, renal disease, respiratory disease, rheumatic disease and 
stroke).
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In separated analyses of outpatients and inpatients, 
vaccination only in the current season was protective 
for primary healthcare consultations but not for hospi-
talisations. In hospitalised patients however, a history 
of vaccination in the prior seasons appeared to confer 
enhanced protection, whether the inpatients were vac-
cinated or not in the current season (Figure).
Discussion and conclusion
Estimates of VE during the influenza season help guide 
health interventions aimed at reducing the impact of 
influenza in the population [10] and may help in the 
selection of strains to be contained in the next sea-
son’s vaccine. For the 2016/17 season in Navarre, when 
vaccination status in the prior influenza seasons was 
not considered, we found low VE (15%) in the whole 
pool of patients, null VE for hospitalised patients and 
better protection (48%) for outpatients; the higher 
protection level in outpatients is consistent with the 
early estimates reported from the Canadian Sentinel 
Practitioner Surveillance Network [11]. 
In the analysis considering vaccination history; how-
ever, better levels of protection were observed for 
many of the combinations of current and prior sea-
son vaccination, especially for hospitalised patients. 
The results of the overall analysis suggest that the 
protective effect of the influenza vaccination against 
A(H3N2) virus in Navarre in the early 2016/17 season 
ranged from 24% to 61%, depending on the vaccination 
status in the current and prior seasons.
The VE estimates were strongly related to the vaccina-
tion history. One or two vaccine doses over the four 
prior seasons maintained or increased the protection 
of the current season vaccination, but three or more 
prior doses had a negative interference with the cur-
rent season vaccine effect. A similar interference was 
described in previous seasons by other authors [8,12], 
and inverse exposure-response association has been 
reported between repeated influenza vaccination and 
haemagglutinin antibodies titres for A(H3N2) virus [13].
Our results obtained from two independently recruited 
groups, inpatients and outpatients, were broadly con-
sistent. The main difference was that vaccination only 
in the current season was protective for influenza cases 
attended in primary healthcare but not against influ-
enza hospitalisations, which may be due to the poorer 
immune response among patients that need hospitali-
sation. Especially remarkable is the preventive effect 
observed for the vaccine doses received in prior sea-
sons in individuals without current season vaccination.
Table 2
Influenza vaccine effectiveness in preventing laboratory-confirmed influenza A(H3N2) among individuals ≥ 9 years-old in 








Both healthcare settings 
All swabbed patients 322/327 240/351 31 (13 to 45) 15 (−11 to 35)
Target group for vaccinationb 307/218 225/184 13 (−13 to 33) 16 (−12 to 37)
Age group in years
9−64 56/192 37/239 47 (16 to 66) 24 (−26 to 55)
≥ 65 266/135 203/112 8 (−25 to 33) 11 (−23 to 35)
Hospitalised patients 
All swabbed patients 278/205 187/113 −22 (−64 to 9) 0 (−38 to 27)
Target group for vaccinationb 272/175 185/104 −14 (−55 to 16) 2 (−36 to 29)
Age group in years
9−64 33/83 14/27 −30 (−179 to 39) −27 (−188 to 44)
≥ 65 245/122 173/86 0 (−40 to 29) 5 (−34 to 33)
Primary healthcare patients 
All swabbed patients 44/122 53/238 38 (3 to 61) 48 (−1 to 65)
Target group for vaccinationb 35/43 40/80 39 (−10 to 66) 54 (10 to 77)
Age group in years
9−64 23/109 23/212 49 (4 to 72) 43 (−8 to 70)
≥ 65 21/13 30/26 29 (−70 to 70) 44 (−41 to 78)
CI: confidence interval; VE: vaccine effectiveness.
a Logistic regression model adjusted for sex, age group (9–24, 25–44, 45–64, 65–85 and ≥ 85 years), major chronic conditions, month of 
swabbing and healthcare setting (primary healthcare and hospital).
b Target group for vaccination includes people ≥ 60 years old and people with major chronic conditions (body mass index ≥40 kg/m2, cancer, 
liver cirrhosis, dementia, diabetes mellitus, immunodeficiency, heart disease, renal disease, respiratory disease, rheumatic disease and 
stroke).
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This study has some limitations. Natural immunity due 
to exposure to influenza virus was not considered; how-
ever, in a previous study we demonstrated that it was 
not a relevant confounding factor or effect modifier of 
influenza VE [7]. Since these results are preliminary and 
have limited statistical power for some analyses, the 
final results for the season may be different. The study 
compared laboratory-confirmed cases with controls 
recruited in the same settings before either patient 
or physician knew the laboratory result, an approach 
that reduced selection bias [14]. We included patients 
recruited in primary care and hospitals, thus achiev-
ing representation of the whole spectrum of patients 
with influenza. The healthcare setting could have acted 
as a confounding factor, therefore the analyses were 
adjusted for this variable. This study evaluates a par-
ticular situation of circulating virus and composition of 
the vaccines; caution should be taken in generalising 
its outcome.
In conclusion, the results suggest that, overall, the dif-
ferent combinations of vaccination in the current and 
prior seasons were moderately effective against influ-
enza A(H3N2) in the early 2016/17 season in northern 
Spain. In spite of the possible interferences between 
the effects of the current season vaccine and frequent 
prior vaccination, these findings highlight the net ben-
efit of immunisation against influenza.
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